Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in...

Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco ( Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India )

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma...

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in...

Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma ( Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type...

Dr Veronica Conca - University of Pisa, Pisa, Italy

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC ( Dr Veronica Conca - University of Pisa, Pisa, Italy )

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible...

Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam...

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma ( Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Long-term infusion of dinutuximab beta improves survival in high-risk...

Dr Ruth Ladenstein - St. Anna Children's Hospital, Vienna, Austria

Long-term infusion of dinutuximab beta improves survival in high-risk neuroblastoma ( Dr Ruth Ladenstein - St. Anna Children's Hospital, Vienna, Austria )

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous...

Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma ( Dr Danny Rischin - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer